Identification

Name
Naproxen
Accession Number
DB00788  (APRD01135, DB08298)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.

Structure
Thumb
Synonyms
  • (+)-(S)-6-Methoxy-α-methyl-2-naphthaleneacetic acid
  • (+)-(S)-Naproxen
  • (+)-2-(6-Methoxy-2-naphthyl)propionic acid
  • (+)-2-(Methoxy-2-naphthyl)-propionic acid
  • (+)-2-(Methoxy-2-naphthyl)-propionsäure
  • (+)-Naproxen
  • (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid
  • (S)-(+)-Naproxen
  • (S)-2-(6-Methoxy-2-naphthyl)propanoic acid
  • (S)-2-(6-Methoxy-2-naphthyl)propionic acid
  • (S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
  • (S)-Naproxen
  • Naprolag
  • Naproxen
  • Naproxène
  • Naproxeno
  • Naproxenum
External IDs
RS 3540 / RS 3650 / RS-3540
Product Ingredients
IngredientUNIICASInChI Key
Naproxen sodium9TN87S3A3C26159-34-2CDBRNDSHEYLDJV-FVGYRXGTSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AnaproxTablet275 mgOralAtnahs Pharma Uk Limited1995-12-31Not applicableCanada
AnaproxTablet275 mgOralSyntex Inc.1980-12-311996-09-30Canada
AnaproxTablet275 mg/1OralGenentech, Inc.1980-09-042017-01-31Us
Anaprox DSTablet550 mg/1OralCanton Laboratories2016-06-01Not applicableUs
Anaprox DSTablet550 mgOralAtnahs Pharma Uk Limited1995-12-31Not applicableCanada
Anaprox DSTablet550 mg/1OralGenentech, Inc.1980-09-04Not applicableUs
Anaprox DS Tab 550mgTablet550 mgOralSyntex Inc.1990-12-311996-09-30Canada
Ava-naproxen ECTablet, delayed release500 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-naproxen ECTablet, delayed release250 mgOralAvanstra Inc2011-10-112014-08-21Canada
EC-NaprosynTablet, delayed release500 mg/1OralCanton Laboratories2016-06-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
All Day ReliefTablet220 mg/1OralRemedy Repack2015-03-092017-03-14Us
AnaproxTablet550 mg/1OralDirectrx2016-07-11Not applicableUs
Apo Naproxen Tab 125mgTablet125 mgOralApotex Corporation1982-12-31Not applicableCanada
Apo-napro-NATablet275 mgOralApotex Corporation1989-12-31Not applicableCanada
Apo-napro-NA DSTablet550 mgOralApotex Corporation1993-12-31Not applicableCanada
Apo-naproxenTablet250 mgOralApotex Corporation1982-12-31Not applicableCanada
Apo-naproxenTablet500 mgOralApotex Corporation1983-12-31Not applicableCanada
Apo-naproxenTablet375 mgOralApotex Corporation1983-12-31Not applicableCanada
Apo-naproxen ECTablet, delayed release500 mgOralApotex Corporation2003-04-23Not applicableCanada
Apo-naproxen ECTablet, delayed release375 mgOralApotex Corporation2003-04-23Not applicableCanada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
7 Select Naproxen SodiumTablet220 mg/1Oral7 Eleven2014-08-11Not applicableUs
7 Select Naproxen SodiumTablet, film coated220 mg/1Oral7 Eleven2014-08-05Not applicableUs
AleveTablet220 mg/1OralLil' Drug Store Products, Inc.2000-01-01Not applicableUs
AleveTablet220 mgOralBayer2009-06-15Not applicableCanada
AleveTablet220 mg/1OralBayer Health Care Llc.2002-07-26Not applicableUs
AleveTablet220 mg/1OralNavajo Manuracturing Company2016-09-17Not applicableUs
AleveTablet220 mg/1OralCardinal Health1994-01-11Not applicableUs
AleveTablet220 mg/1OralR J General Corporation2014-02-26Not applicableUs
AleveCapsule, liquid filled220 mg/1OralBayer Health Care Llc.2007-02-20Not applicableUs
Aleve Back and Body PainCapsule220 mgOralBayer2015-06-30Not applicableCanada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Equipto - Naproxen External Cream Compounding KitKitTopicalAlvix Laboratories2015-01-20Not applicableUs
International/Other Brands
Alidase (Laboratorios) / Alpoxen (Actavis) / Alpron (Aldril) / Apain (Marvic) / Apranax (Roche) / Apronax (Bayer) / Bonyl (Orion) / Bruproxen (Bruluart) / Bumaflex N (Nycomed) / Congex (Buxton) / Debril (Monserrat) / Deproxen (Drug International) / Dysmenalgit (Krewel Meuselbach) / Emox (Emo-Farm) / Emoxen (EMO) / Eurogesic (Saval) / Fabralgina (Fabra) / Feminax Ultra (Bayer) / Flogotone (Interpharma) / Gerinap (Gerard) / Honlow (Panion & BF) / Improstan (Farmacoop) / Inflamax (Farmaceutica) / Inza (Alphapharm) / Iraxen (Quilab) / Jinkangpuli (Conba) / Lexinax (Brisafarma) / Melgar (Hexa) / Messelxen (Biomep) / Mobilat (STADA) / Naprometin (Roche) / Naprosyn CR (Abdi Ibrahim) / Naprosyn EC (Roche) / Naprosyn Entero (Roche) / Naprosyn SR (Roche) / Naprosyne (Roche) / Naproval (Labinco) / Naprux (Andromaco) / Neuralprona (Lba) / Noflam (Mylan) / Nopain (Medicef) / Prexan (New Research) / Priaxen (Remedica) / Princeps (Laser ) / Pronaxen (Orion) / Proxen (Grünenthal) / Proxen S (Roche) / Proxen SR (Roche) / Releve (General Pharma) / Repro (Doctor's Chemical Works) / Reuxen (Helcor) / Riproxen (BioGenet) / Sanaprox (Perumed) / Seladin (YSP) / Servinaprox (Novartis) / Tarproxen (Polfa Tarchomin) / Ticoflex (Incepta) / Tundra (Frasca) / Xenar (Elder) / Xenar-CR (Elder)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Aleve NighttimeNaproxen sodium (220 mg) + Diphenhydramine hydrochloride (25 mg)TabletOralBayer2016-02-24Not applicableCanada
Aleve PMNaproxen sodium (220 mg/1) + Diphenhydramine hydrochloride (25 mg/1)Tablet, film coatedOralBayer Health Care Llc.2014-09-09Not applicableUs
Aleve-D Sinus and ColdNaproxen sodium (220 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)TabletOralBayer Health Care Llc.2014-01-01Not applicableUs
Aleve-D Sinus and HeadacheNaproxen sodium (220 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)TabletOralBayer Health Care Llc.2014-01-01Not applicableUs
All Day Sinus and Cold DNaproxen sodium (220 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, film coatedOralHyvee2013-08-12Not applicableUs
All Day Sinus and Cold DNaproxen sodium (220 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, film coatedOralWalgreen2013-05-23Not applicableUs
Good Neighbor Pharmacy Sinus and Cold DNaproxen sodium (220 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, film coatedOralAmerisource Bergen2013-08-22Not applicableUs
Health Mart Sinus and Cold DNaproxen sodium (220 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, film coatedOralMc Kesson2013-08-15Not applicableUs
Leader Sinus and Cold-DNaproxen sodium (220 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, film coatedOralCardinal Health2017-06-07Not applicableUs
Leader Sinus and Cold-DNaproxen sodium (220 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, film coatedOralCardinal Health2013-11-05Not applicableUs
Categories
UNII
57Y76R9ATQ
CAS number
22204-53-1
Weight
Average: 230.2592
Monoisotopic: 230.094294314
Chemical Formula
C14H14O3
InChI Key
CMWTZPSULFXXJA-VIFPVBQESA-N
InChI
InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
IUPAC Name
(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
SMILES
COC1=CC2=C(C=C1)C=C(C=C2)[[email protected]](C)C(O)=O

Pharmacology

Indication

For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, and acute gout. Also for the relief of mild to moderate pain and the treatment of primary dysmenorrhea.

Structured Indications
Pharmacodynamics

Naproxen is a member of the arylacetic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Naproxen has analgesic and antipyretic properties. As with other NSAIDs, its mode of action is not fully understood; however, its ability to inhibit prostaglandin synthesis may be involved in the anti-inflammatory effect.

Mechanism of action

The mechanism of action of naproxen, like that of other NSAIDs, is believed to be associated with the inhibition of cyclooxygenase activity. Two unique cyclooxygenases have been described in mammals. The constitutive cyclooxygenase, COX-1, synthesizes prostaglandins necessary for normal gastrointestinal and renal function. The inducible cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is thought to be associated with gastrointestinal and renal toxicity while inhibition of COX-2 provides anti-inflammatory activity.

TargetActionsOrganism
AProstaglandin G/H synthase 1
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
UPeptostreptococcal albumin-binding proteinNot AvailablePeptostreptococcus magnus
Absorption

Naproxen itself is rapidly and completely absorbed from the GI tract with an in vivo bioavailability of 95%. Although naproxen itself is well absorbed, the sodium salt form is more rapidly absorbed resulting in higher peak plasma levels for a given dose. Food causes a slight decrease in the rate absorption.

Volume of distribution
Not Available
Protein binding

At therapeutic levels naproxen is greater than 99% albumin-bound.

Metabolism

Naproxen is extensively metabolized to 6-0-desmethyl naproxen and both parent and metabolites do not induce metabolizing enzymes.

Route of elimination
Not Available
Half life

The observed terminal elimination half-life is approximately 15 hours.

Clearance
Not Available
Toxicity

ORAL (LD50): Acute: 248 mg/kg [Rat]. 360 mg/kg [Mouse]. Symptoms of overdose include drowsiness, heartburn, indigestion, nausea, and vomiting.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Naproxen Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Naproxen is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Naproxen is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Naproxen is combined with 5-androstenedione.Experimental, Illicit
AbciximabNaproxen may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Naproxen can be increased when it is combined with Abiraterone.Approved
AcebutololNaproxen may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Naproxen is combined with Aceclofenac.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Naproxen is combined with Acemetacin.Approved
AcenocoumarolNaproxen may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Naproxen is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinNaproxen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Naproxen.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Naproxen is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Naproxen is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Naproxen is combined with Alendronic acid.Approved
AliskirenNaproxen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Alminoprofen.Experimental
AlprenololNaproxen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Naproxen.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Naproxen is combined with Amcinonide.Approved
AmikacinNaproxen may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideNaproxen may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Naproxen can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinNaproxen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodNaproxen may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Naproxen is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Naproxen is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Naproxen is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Naproxen is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Naproxen is combined with Anisodamine.Investigational
annamycinNaproxen may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Naproxen is combined with Antipyrine.Approved
Antithrombin III humanNaproxen may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Naproxen is combined with Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Naproxen is combined with Apocynin.Investigational
ApramycinNaproxen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Naproxen is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Naproxen can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinNaproxen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinNaproxen may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanNaproxen may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololNaproxen may decrease the antihypertensive activities of Arotinolol.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Naproxen is combined with Atamestane.Investigational
AtenololNaproxen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Naproxen is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Naproxen.Approved
AzithromycinThe metabolism of Naproxen can be decreased when combined with Azithromycin.Approved
BalsalazideNaproxen may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminNaproxen may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Naproxen is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololNaproxen may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinNaproxen may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Naproxen.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Naproxen is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Naproxen.Approved
BenorilateThe risk or severity of adverse effects can be increased when Naproxen is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Naproxen.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Betamethasone.Approved, Vet Approved
BetaxololNaproxen may decrease the antihypertensive activities of Betaxolol.Approved
BevantololNaproxen may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Naproxen is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Naproxen.Approved, Investigational
BisoprololNaproxen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinNaproxen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololNaproxen may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Naproxen can be decreased when combined with Bortezomib.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Naproxen is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Naproxen is combined with Bucillamine.Investigational
BucindololNaproxen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Naproxen is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Naproxen is combined with Bufexamac.Experimental
BufuralolNaproxen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Bumadizone.Experimental
BumetanideNaproxen may decrease the diuretic activities of Bumetanide.Approved
BupranololNaproxen may decrease the antihypertensive activities of Bupranolol.Approved
CaffeineThe metabolism of Naproxen can be decreased when combined with Caffeine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Naproxen.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Naproxen.Experimental
CapecitabineThe metabolism of Naproxen can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Naproxen.Approved
CarbamazepineThe metabolism of Naproxen can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Naproxen is combined with Carbaspirin calcium.Experimental
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Naproxen.Approved
CarprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololNaproxen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolNaproxen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Naproxen is combined with Castanospermine.Experimental
CelecoxibThe metabolism of Naproxen can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololNaproxen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Naproxen can be increased when it is combined with Ceritinib.Approved
CertoparinNaproxen may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Naproxen.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Naproxen.Approved
CholecalciferolThe metabolism of Naproxen can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Naproxen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Naproxen is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Naproxen is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Naproxen.Approved
CinoxacinNaproxen may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CitalopramThe metabolism of Naproxen can be decreased when combined with Citalopram.Approved
Citric AcidNaproxen may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Naproxen is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Naproxen is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Naproxen is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Naproxen is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Naproxen is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Naproxen.Vet Approved
CloranololNaproxen may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Naproxen can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Naproxen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Naproxen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Naproxen is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Naproxen is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Naproxen is combined with Cortisone acetate.Approved
CrisaboroleThe metabolism of Naproxen can be decreased when combined with Crisaborole.Approved
CurcuminThe risk or severity of adverse effects can be increased when Naproxen is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Naproxen.Experimental
CyclosporineNaproxen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Naproxen can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when Naproxen is combined with D-Limonene.Investigational
Dabigatran etexilateNaproxen may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Naproxen can be decreased when it is combined with Dabrafenib.Approved
DalteparinNaproxen may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidNaproxen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanNaproxen may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinNaproxen may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Naproxen can be increased when it is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Naproxen.Experimental
DelavirdineThe metabolism of Naproxen can be decreased when combined with Delavirdine.Approved
DesirudinNaproxen may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Naproxen is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Naproxen is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Naproxen is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Naproxen is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Naproxen.Approved
DextranNaproxen may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Naproxen may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Naproxen may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Naproxen may increase the anticoagulant activities of Dextran 75.Approved
DibekacinNaproxen may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Naproxen.Approved, Vet Approved
DicoumarolNaproxen may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Naproxen is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Naproxen is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Naproxen is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Naproxen is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Naproxen.Approved
DihydrostreptomycinNaproxen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Naproxen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Naproxen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Naproxen.Approved
DosulepinThe metabolism of Naproxen can be decreased when combined with Dosulepin.Approved
DoxorubicinNaproxen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneNaproxen may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Naproxen is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Naproxen is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Naproxen is combined with E-6201.Investigational
Edetic AcidNaproxen may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanNaproxen may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Naproxen can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Naproxen.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Naproxen.Approved
EnoxacinNaproxen may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinNaproxen may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Naproxen.Experimental
EpanololNaproxen may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Naproxen is combined with Epirizole.Approved
EpirubicinNaproxen may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneNaproxen may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Naproxen.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Naproxen.Approved
EquileninThe risk or severity of adverse effects can be increased when Naproxen is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Naproxen is combined with Equilin.Approved
EsmololNaproxen may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Naproxen is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Naproxen is combined with Estrone sulfate.Approved
Etacrynic acidNaproxen may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Naproxen.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Naproxen is combined with Ethenzamide.Experimental
Ethyl biscoumacetateNaproxen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Naproxen is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Naproxen is combined with Etofenamate.Approved
EtravirineThe metabolism of Naproxen can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Naproxen is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Naproxen is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Naproxen is combined with Felbinac.Experimental
FelodipineThe metabolism of Naproxen can be decreased when combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Naproxen is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Naproxen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Naproxen.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Naproxen is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Feprazone.Experimental
Ferulic acidNaproxen may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Naproxen.Approved
FleroxacinNaproxen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Naproxen.Approved, Withdrawn
FloxuridineThe metabolism of Naproxen can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Naproxen is combined with fluasterone.Investigational
FluconazoleThe metabolism of Naproxen can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Fludrocortisone.Approved
FluindioneNaproxen may increase the anticoagulant activities of Fluindione.Investigational
FlumequineNaproxen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Flumethasone.Approved, Vet Approved
FlunixinThe risk or severity of adverse effects can be increased when Naproxen is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Naproxen is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Naproxen is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Naproxen is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Naproxen can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Naproxen is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Naproxen is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Naproxen.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Naproxen is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Naproxen.Approved, Investigational
FluvastatinThe metabolism of Naproxen can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Naproxen can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Naproxen.Approved, Nutraceutical, Vet Approved
FondaparinuxNaproxen may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumNaproxen may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Naproxen.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Naproxen is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Naproxen.Approved
FosphenytoinThe metabolism of Naproxen can be increased when combined with Fosphenytoin.Approved
FramycetinNaproxen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideNaproxen may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateNaproxen may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinNaproxen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinNaproxen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Naproxen.Approved, Withdrawn
GemfibrozilThe metabolism of Naproxen can be decreased when combined with Gemfibrozil.Approved
GemifloxacinNaproxen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinNaproxen may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinNaproxen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ANaproxen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Naproxen may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinNaproxen may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Naproxen is combined with Guacetisal.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Naproxen is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Naproxen is combined with HE3286.Investigational
HeparinNaproxen may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Naproxen is combined with Higenamine.Investigational
HydralazineNaproxen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Naproxen.Approved
Hygromycin BNaproxen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Naproxen is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Naproxen is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Naproxen is combined with Icatibant.Approved
IdarubicinNaproxen may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxNaproxen may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Naproxen.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Naproxen.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Naproxen is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Naproxen.Approved
IndenololNaproxen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Naproxen can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Naproxen is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Naproxen.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Indoprofen.Withdrawn
INNO-206Naproxen may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Naproxen can be decreased when combined with Irbesartan.Approved, Investigational
IsepamicinNaproxen may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Naproxen is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Naproxen is combined with Istaroxime.Investigational
KanamycinNaproxen may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Naproxen can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Naproxen.Approved
LabetalolNaproxen may decrease the antihypertensive activities of Labetalol.Approved
LandiololNaproxen may decrease the antihypertensive activities of Landiolol.Investigational
LapatinibThe metabolism of Naproxen can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Naproxen.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Naproxen.Investigational
LeflunomideThe metabolism of Naproxen can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinNaproxen may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanNaproxen may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololNaproxen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinNaproxen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LidocaineThe metabolism of Naproxen can be decreased when combined with Lidocaine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Naproxen.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Naproxen.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Naproxen is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Naproxen.Approved
LobeglitazoneThe metabolism of Naproxen can be decreased when combined with Lobeglitazone.Approved
LonazolacThe risk or severity of adverse effects can be increased when Naproxen is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Naproxen is combined with Lornoxicam.Approved
LosartanThe metabolism of Naproxen can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Naproxen can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Naproxen.Approved, Investigational
LumacaftorThe serum concentration of Naproxen can be increased when it is combined with Lumacaftor.Approved
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Naproxen.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Naproxen is combined with Magnesium salicylate.Approved
ManidipineThe metabolism of Naproxen can be decreased when combined with Manidipine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Naproxen.Approved
ME-609The risk or severity of adverse effects can be increased when Naproxen is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Naproxen is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Naproxen.Approved
MelagatranNaproxen may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Naproxen is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Naproxen is combined with Meloxicam.Approved, Vet Approved
MepindololNaproxen may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineNaproxen may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Naproxen is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Naproxen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Naproxen.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Naproxen is combined with Methylprednisolone.Approved, Vet Approved
MetipranololNaproxen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Naproxen.Approved
MetoprololNaproxen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideNaproxen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MexiletineThe metabolism of Naproxen can be decreased when combined with Mexiletine.Approved
MicronomicinNaproxen may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Naproxen can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Naproxen can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Naproxen.Approved
MizoribineThe risk or severity of adverse effects can be increased when Naproxen is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Naproxen.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Mofebutazone.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Naproxen.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Naproxen.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Naproxen is combined with Mycophenolic acid.Approved
NadololNaproxen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinNaproxen may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNaproxen may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Naproxen.Approved
Nalidixic AcidNaproxen may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NCX 1022The risk or severity of adverse effects can be increased when Naproxen is combined with NCX 1022.Investigational
NeamineNaproxen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinNaproxen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinNaproxen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Naproxen is combined with Nepafenac.Approved
NetilmicinNaproxen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NevirapineThe metabolism of Naproxen can be decreased when combined with Nevirapine.Approved
NicardipineThe metabolism of Naproxen can be decreased when combined with Nicardipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Naproxen is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Naproxen can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Naproxen is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Naproxen is combined with Nitroaspirin.Investigational
NorfloxacinNaproxen may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Naproxen is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Naproxen.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Naproxen.Approved
OlsalazineNaproxen may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Naproxen is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Naproxen.Investigational
OmeprazoleThe metabolism of Naproxen can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Naproxen is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Naproxen can be decreased when it is combined with Osimertinib.Approved
OtamixabanNaproxen may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Naproxen is combined with Oxaprozin.Approved
Oxolinic acidNaproxen may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololNaproxen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Naproxen is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Paramethasone.Approved
ParomomycinNaproxen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Naproxen is combined with Parthenolide.Investigational
PazufloxacinNaproxen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinNaproxen may increase the neuroexcitatory activities of Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Naproxen can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololNaproxen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateNaproxen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Naproxen.Approved
PhenindioneNaproxen may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Naproxen can be increased when combined with Phenobarbital.Approved
PhenprocoumonNaproxen may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Naproxen can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Naproxen.Approved, Investigational
PindololNaproxen may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Naproxen can be decreased when combined with Pioglitazone.Approved, Investigational
Pipemidic acidNaproxen may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinNaproxen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideNaproxen may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Pirfenidone.Investigational
Piromidic acidNaproxen may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Naproxen.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Pirprofen.Experimental
PlazomicinNaproxen may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinNaproxen may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Naproxen.Approved
PractololNaproxen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Naproxen.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Pranoprofen.Experimental
PrasteroneThe risk or severity of adverse effects can be increased when Naproxen is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Naproxen is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Naproxen is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Naproxen is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Naproxen is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Naproxen can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Naproxen can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Naproxen is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Naproxen is combined with Propacetamol.Approved
PropranololNaproxen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Naproxen.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Naproxen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Naproxen.Vet Approved
Protein CNaproxen may increase the anticoagulant activities of Protein C.Approved
Protein S humanNaproxen may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeNaproxen may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinNaproxen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Naproxen is combined with PTC299.Investigational
PuromycinNaproxen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Naproxen can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Naproxen.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Naproxen.Approved
QuinineThe metabolism of Naproxen can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Naproxen can be decreased when combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Naproxen.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Naproxen.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Naproxen is combined with Resveratrol.Experimental, Investigational
ReviparinNaproxen may increase the anticoagulant activities of Reviparin.Approved
RibostamycinNaproxen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifampicinThe metabolism of Naproxen can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Naproxen can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Naproxen is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Naproxen is combined with Risedronate.Approved, Investigational
RivaroxabanNaproxen may increase the anticoagulant activities of Rivaroxaban.Approved
RopiniroleThe metabolism of Naproxen can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Naproxen can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinNaproxen may increase the neuroexcitatory activities of Rosoxacin.Approved
RufloxacinNaproxen may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinNaproxen may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Naproxen.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Naproxen is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Naproxen is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Naproxen is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Naproxen.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Naproxen.Investigational
SecobarbitalThe metabolism of Naproxen can be increased when combined with Secobarbital.Approved, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Naproxen is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Naproxen is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Naproxen is combined with Serrapeptase.Investigational
SildenafilThe metabolism of Naproxen can be decreased when combined with Sildenafil.Approved, Investigational
SimeprevirThe metabolism of Naproxen can be decreased when combined with Simeprevir.Approved
SisomicinNaproxen may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinNaproxen may increase the neuroexcitatory activities of Sitafloxacin.Experimental
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Naproxen.Approved
SorafenibThe metabolism of Naproxen can be decreased when combined with Sorafenib.Approved, Investigational
SotalolNaproxen may decrease the antihypertensive activities of Sotalol.Approved
SP1049CNaproxen may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinNaproxen may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinNaproxen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Naproxen.Approved
SpironolactoneNaproxen may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Naproxen is combined with SRT501.Investigational
StreptomycinNaproxen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinNaproxen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Naproxen can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Naproxen can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Naproxen is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Naproxen can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Naproxen.Approved
SulodexideNaproxen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Naproxen.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Naproxen is combined with Suxibuzone.Experimental
TacrolimusNaproxen may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Naproxen.Approved
TalinololNaproxen may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Naproxen.Approved
TamoxifenThe metabolism of Naproxen can be decreased when combined with Tamoxifen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Naproxen is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Naproxen.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Naproxen is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Naproxen is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Naproxen.Approved, Investigational
TemafloxacinNaproxen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Naproxen.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Naproxen is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Naproxen is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Naproxen.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Naproxen is combined with Tepoxalin.Vet Approved
TeriflunomideThe serum concentration of Naproxen can be decreased when it is combined with Teriflunomide.Approved
TertatololNaproxen may decrease the antihypertensive activities of Tertatolol.Experimental
TheophyllineThe metabolism of Naproxen can be decreased when combined with Theophylline.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Naproxen is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Naproxen can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Naproxen can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Naproxen is combined with Tiludronic acid.Approved, Vet Approved
TimololNaproxen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Naproxen is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Naproxen is combined with Tixocortol.Approved
TobramycinNaproxen may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Naproxen can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Naproxen is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Naproxen.Approved
TopiroxostatThe metabolism of Naproxen can be decreased when combined with Topiroxostat.Approved
TorasemideNaproxen may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Naproxen.Approved
TranilastThe risk or severity of adverse effects can be increased when Naproxen is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Naproxen.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Naproxen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Naproxen is combined with Triamcinolone.Approved, Vet Approved
TriamtereneNaproxen may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Naproxen is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
TrimethoprimThe metabolism of Naproxen can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Naproxen is combined with Triptolide.Investigational
TrovafloxacinNaproxen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
TroxerutinNaproxen may increase the anticoagulant activities of Troxerutin.Investigational
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Naproxen.Approved
Valproic AcidThe metabolism of Naproxen can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinNaproxen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Naproxen can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Naproxen.Approved
VemurafenibThe serum concentration of Naproxen can be increased when it is combined with Vemurafenib.Approved
VoriconazoleThe metabolism of Naproxen can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinNaproxen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranNaproxen may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Naproxen can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Naproxen is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Naproxen.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Naproxen.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Naproxen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Naproxen is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinNaproxen may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinNaproxen may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
ZucapsaicinThe metabolism of Naproxen can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Avoid alcohol.
  • Take with a full glass of water.
  • Take with food.

References

Synthesis Reference
US4009197
General References
  1. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006 Jun 3;332(7553):1302-8. [PubMed:16740558]
  2. Zhang J, Ding EL, Song Y: Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006 Oct 4;296(13):1619-32. Epub 2006 Sep 12. [PubMed:16968832]
External Links
Human Metabolome Database
HMDB01923
KEGG Drug
D00118
KEGG Compound
C01517
ChemSpider
137720
BindingDB
50339185
ChEBI
7476
ChEMBL
CHEMBL154
Therapeutic Targets Database
DAP000968
PharmGKB
PA450595
HET
NPS
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Naproxen
ATC Codes
M01AE02 — NaproxenM01AE52 — Naproxen and esomeprazoleM01AE56 — Naproxen and misoprostolM02AA12 — NaproxenG02CC02 — Naproxen
AHFS Codes
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
  • 56:28.36 — Proton-pump Inhibitors
PDB Entries
2vdb / 3nt1 / 3r58 / 4fjp / 4jq1 / 4or0 / 4ot2 / 4po0 / 4zbr / 5dby
FDA label
Download (240 KB)
MSDS
Download (75.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentOssification, Heterotopic1
0CompletedBasic ScienceSynovitis of osteoarthritis1
1Active Not RecruitingPreventionLynch Syndrome1
1CompletedNot AvailableGastroduodenal Erosions1
1CompletedNot AvailableHealthy Volunteers3
1CompletedNot AvailableHealthy Volunteers / Pharmacodynamic Interaction1
1CompletedNot AvailableMigraine Disorders / Migraines1
1CompletedNot AvailableOsteoarthritis Thumbs1
1CompletedNot AvailablePharmacokinetics1
1CompletedNot AvailableTherapeutic Equivalence1
1CompletedBasic ScienceArthritis2
1CompletedBasic ScienceBioequivalence / Healthy Volunteers1
1CompletedBasic ScienceGout Acute1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic ScienceJuvenile Idiopathic Arthritis (JIA)1
1CompletedBasic ScienceRenal Hemodynamics1
1CompletedDiagnosticSynovitis of osteoarthritis1
1CompletedTreatmentBioavailability1
1CompletedTreatmentBioequivalency2
1CompletedTreatmentGastrointestinal Lesions1
1CompletedTreatmentHealthy Volunteers6
1CompletedTreatmentHematology / Pain1
1CompletedTreatmentOsteoarthritis of the Knees2
1CompletedTreatmentPain2
1CompletedTreatmentPain, Acute1
1CompletedTreatmentPharmacokinetics1
1CompletedTreatmentSynovitis of osteoarthritis1
1RecruitingOtherHealthy Volunteers1
1TerminatedBasic ScienceHealthy Volunteers1
1TerminatedBasic ScienceHealthy Volunteers / Pharmacodynamics of ASP7657 / Pharmacokinetics of ASP76571
1TerminatedTreatmentHealthy Volunteers1
1Unknown StatusTreatmentTMD1
1, 2CompletedTreatmentHealthy Volunteers1
1, 2CompletedTreatmentPain Management / Pulpitis dental1
1, 2RecruitingPreventionGastric Ulcer (GU)1
2Active Not RecruitingTreatmentOsteoarthritis of the Knees1
2Active Not RecruitingTreatmentPleural Effusion Malignant / Pleural Effusions1
2CompletedNot AvailableSynovitis of osteoarthritis1
2CompletedPreventionAlzheimer's Disease (AD) / Cognitive Decline Due to Alzheimer Disease / Mild Cognitive Impairment Due to Alzheimer's Disease1
2CompletedPreventionErosion / Gastroduodenal Ulcerations1
2CompletedTreatmentBone Pain in Stage I - III Breast Cancer1
2CompletedTreatmentChronic Low Back Pain (CLBP)1
2CompletedTreatmentChronic Lower Back Pain / Osteoarthritis of the Knees1
2CompletedTreatmentDental Pain1
2CompletedTreatmentGout Acute / Moderate Renal Impairment1
2CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentLow Back Pain (LBP)2
2CompletedTreatmentOsteoarthritis of the Knees2
2CompletedTreatmentOsteoarthritis of the Knees / Pain1
2CompletedTreatmentPain3
2CompletedTreatmentPharyngitis1
2CompletedTreatmentRheumatoid Arthritis1
2CompletedTreatmentSynovitis of osteoarthritis2
2RecruitingPreventionPain, Neuropathic1
2TerminatedTreatmentOsteoarthritis of the Knees1
2TerminatedTreatmentProstate Cancer / Prostatic Neoplasms1
2TerminatedTreatmentSynovitis of osteoarthritis1
2WithdrawnTreatmentPain, Acute1
2, 3CompletedTreatmentAdolescent Migraine / Migraines1
2, 3CompletedTreatmentAlzheimer's Disease (AD)1
2, 3CompletedTreatmentIdiopathic Intracranial Hypertension (IIH)1
2, 3CompletedTreatmentSynovitis of osteoarthritis1
2, 3WithdrawnTreatmentHIV-infection/Aids / Immune Reconstitution Inflammatory Syndrome / Immune Reconstitution Syndrome / Tuberculosis1
3CompletedNot AvailablePain2
3CompletedPreventionAlzheimer's Disease (AD)1
3CompletedPreventionAnkylosing Spondylitis (AS) / Rheumatoid Arthritis / Synovitis of osteoarthritis1
3CompletedSupportive CareMusculoskeletal Complications / Pain / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentAnkylosing Spondylitis (AS) / Spondyloarthritis, Axial1
3CompletedTreatmentArthritis, Juvenile Rheumatoid3
3CompletedTreatmentArthritis / Cardiovascular Disease (CVD) / Cerebrovascular Disorders1
3CompletedTreatmentArthritis / Synovitis of osteoarthritis1
3CompletedTreatmentDysmenorrhea1
3CompletedTreatmentGastric Ulcer (GU)3
3CompletedTreatmentGout Acute1
3CompletedTreatmentKnee / Synovitis of osteoarthritis1
3CompletedTreatmentLow Back Pain (LBP)1
3CompletedTreatmentMigraine Disorders1
3CompletedTreatmentMigraine Disorders / Migraine, Acute1
3CompletedTreatmentMigraine, Without Aura1
3CompletedTreatmentMigrainous Headache3
3CompletedTreatmentOsteoarthritis of the Knees1
3CompletedTreatmentOsteoarthritis of the Knees / Osteoarthritis, Hip1
3CompletedTreatmentOsteoarthritis, Hip / Synovitis of osteoarthritis1
3CompletedTreatmentPain1
3CompletedTreatmentPeptic Ulcers / Synovitis of osteoarthritis1
3CompletedTreatmentPostoperative pain3
3CompletedTreatmentRelapsing Multiple Sclerosis (RMS) / Relapsing Remitting Multiple Sclerosis (RRMS)1
3CompletedTreatmentToothache1
3CompletedTreatmentSynovitis of osteoarthritis5
3Not Yet RecruitingTreatmentOsteoarthritis of the Knees / Osteoarthritis, Hip1
3RecruitingTreatmentAcute and Chronic Inflammation / Indigestion1
3TerminatedTreatmentGastric Ulcer (GU)1
3Unknown StatusTreatmentBack Pain2
3WithdrawnTreatmentHeadaches / Migraines2
4Active Not RecruitingTreatmentGout Acute1
4CompletedNot AvailableGastroduodenal Ulcers1
4CompletedNot AvailableMigraines1
4CompletedPreventionMigraines2
4CompletedPreventionPeptic Ulcers1
4CompletedPreventionRheumatoid Arthritis / Synovitis of osteoarthritis1
4CompletedTreatmentAnalgesics1
4CompletedTreatmentAnterior Cruciate Ligament Reconstruction1
4CompletedTreatmentArthritis, Juvenile Rheumatoid1
4CompletedTreatmentBack Pain Lower Back1
4CompletedTreatmentChronic Migraine1
4CompletedTreatmentEpicondylitis of the Elbow1
4CompletedTreatmentEpicondylitis, Lateral Humeral / Lateral Epicondylitis1
4CompletedTreatmentGout Acute1
4CompletedTreatmentHeadache, Tension-Type / Migraines / Primary Headache Disorders1
4CompletedTreatmentHypermenorrhea1
4CompletedTreatmentJuvenile Idiopathic Arthritis (JIA)1
4CompletedTreatmentLow Back Pain (LBP)1
4CompletedTreatmentMenstrual Migraines1
4CompletedTreatmentMigraine Disorders / Migraine With or Without Aura / Migraine, Acute / Migrainous Headache1
4CompletedTreatmentMigraines2
4CompletedTreatmentOsteoarthritis of the Knees1
4CompletedTreatmentPost-Vaginal Delivery Perineal Pain1
4CompletedTreatmentRheumatoid Arthritis3
4CompletedTreatmentSleep1
4CompletedTreatmentSub-acute Back Pain1
4RecruitingBasic SciencePoor Metabolizer Due to Cytochrome P450 CYP2C19 Variant / Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant1
4RecruitingPreventionAnaesthesia therapy / Hip Fractures1
4RecruitingTreatmentChronic Low Back Pain (CLBP)2
4RecruitingTreatmentHypermenorrhea1
4RecruitingTreatmentLigament Injury1
4RecruitingTreatmentLow Back Pain (LBP)1
4RecruitingTreatmentSynovitis of osteoarthritis1
4TerminatedPreventionPost-Traumatic Headaches1
4TerminatedTreatmentHealthy Volunteers1
4Unknown StatusTreatmentAcute Low Back Pain1
4Unknown StatusTreatmentPostoperative Laminectomy Pain / Postoperative pain1
4Unknown StatusTreatmentPostoperative pain1
4WithdrawnPreventionOssification, Heterotopic1
4WithdrawnSupportive CareClosed Fracture of Ankle1
Not AvailableCompletedNot AvailableMigraine Disorders3
Not AvailableCompletedNot AvailableMigraines1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedPreventionContraception / Haemorrhage1
Not AvailableCompletedPreventionTooth Bleaching / Toothache1
Not AvailableCompletedSupportive CareContraception1
Not AvailableCompletedTreatmentContraception / Pain1
Not AvailableCompletedTreatmentOsteoarthritis of the Knees1
Not AvailableCompletedTreatmentRenal Stones1
Not AvailableCompletedTreatmentSynovitis of osteoarthritis4
Not AvailableRecruitingTreatmentGeneral Surgery / Pain / Rib Fractures / Traumas1
Not AvailableRecruitingTreatmentIUD Insertion Complication1
Not AvailableRecruitingTreatmentMigraines1
Not AvailableUnknown StatusNot AvailableCognitive Impairments / Migrainous Headache1
Not AvailableUnknown StatusTreatmentFlail Chest / General Surgery / Rib Fractures / Traumas1
Not AvailableUnknown StatusTreatmentMigraine With Aura1
Not AvailableUnknown StatusTreatmentOsteoarthritis of the Knees1
Not AvailableUnknown StatusTreatmentPain1
Not AvailableWithdrawnSupportive CareToothache1

Pharmacoeconomics

Manufacturers
  • Roche palo alto llc
  • Roxane laboratories inc
  • Actavis elizabeth llc
  • Alphapharm party ltd
  • Pliva inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Amneal pharmaceuticals ny llc
  • Baxter healthcare corp anesthesia and critical care
  • Dava pharmaceuticals inc
  • Glenmark generics ltd
  • Hamilton pharmaceuticals ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Perrigo r and d co
  • Purepac pharmaceutical co
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Westward pharmaceutical corp
  • Zydus pharmaceuticals usa inc
  • Banner pharmacaps inc
  • Stat trade inc
  • Watson laboratories inc florida
  • Bayer healthcare llc
  • Able laboratories inc
  • Contract pharmacal corp
  • Dr reddys laboratories inc
  • Dr reddys laboratories ltd
  • Hikma pharmaceuticals
  • L perrigo co
Packagers
Dosage forms
FormRouteStrength
TabletOral
TabletOral200 mg/1
TabletOral275 mg/1
TabletOral550 mg/1
TabletOral125 mg
CapsuleOral220 mg/1
Tablet, delayed releaseOral375 mg/1
Tablet, delayed releaseOral500 mg/1
KitTopical
Tablet, film coatedOral200 mg/1
Capsule, liquid filledOral220 mg/1
TabletOral220 mg/1
Tablet, film coatedOral220 mg/1
CapsuleOral200 mg
KitOral
Tablet, extended releaseOral375 mg
Tablet, extended releaseOral500 mg
Tablet, film coated, extended releaseOral375 mg/1
Tablet, film coated, extended releaseOral500 mg/1
Tablet, film coated, extended releaseOral750 mg/1
SuspensionOral125 mg/5mL
TabletOral250 mg/1
TabletOral375 mg/1
TabletOral500 mg/1
SuspensionOral25 mg
Tablet, extended releaseOral750 mg
TabletOral220 mg
TabletOral500 mg/500mg
Tablet, film coatedOral275 mg/1
Tablet, film coatedOral550 mg/1
CapsuleOral
Kit
CapsuleOral220 mg
TabletOral200 1/1
TabletOral275 mg
Tablet, coatedOral220 mg/1
Tablet, film coated, extended releaseOral220 mg/1
SuspensionOral125 mg
SuppositoryRectal500 mg
Tablet, film coatedOral
Tablet, film coated, extended releaseOral
TabletOral250 mg
TabletOral375 mg
TabletOral500 mg
Tablet, delayed releaseOral250 mg
Tablet, delayed releaseOral375 mg
Tablet, delayed releaseOral500 mg
TabletOral550 mg
Kit
Tablet, delayed releaseOral
Prices
Unit descriptionCostUnit
Naproxen 125 mg/5ml Suspension 500ml Bottle51.5USD bottle
Naprelan 750 mg 24 Hour tablet8.87USD tablet
Naprelan cr 500 mg tablet8.5USD tablet
Naprelan cr 750 mg tablet8.02USD tablet
Naprelan cr dosecrd 500-750 mg5.98USD each
Naprelan 375 mg 24 Hour tablet4.34USD tablet
Anaprox ds 550 mg tablet3.66USD tablet
Naprelan 500 mg 24 Hour tablet3.63USD tablet
Naprelan cr 375 mg tablet3.52USD tablet
Naproxen sodium powder2.63USD g
Anaprox 275 mg tablet2.52USD tablet
Naprosyn 500 mg tablet2.42USD tablet
Naproxen powder2.26USD g
Naprosyn 500 mg tablet ec2.19USD tablet
Naprosyn 375 mg tablet1.93USD tablet
Ec-naprosyn 375 mg tablet ec1.79USD tablet
Naprosyn 250 mg tablet1.47USD tablet
Naprosyn Sr 750 mg Sustained-Release Tablet1.43USD tablet
Anaprox Ds 550 mg Tablet1.33USD tablet
Naproxen 500 mg tablet1.32USD tablet
Naproxen sodium 550 mg tablet1.32USD tablet
Naproxen DR 500 mg Enteric Coated Tabs1.3USD tab
Naproxen DR 375 mg Enteric Coated Tabs1.11USD tab
Naprosyn E 500 mg Enteric-Coated Tablet1.09USD tablet
Naproxen 375 mg tablet1.08USD tablet
Apo-Naproxen Sr 750 mg Sustained-Release Tablet1.05USD tablet
Pms-Naproxen 500 mg Suppository0.87USD suppository
Naproxen sodium 275 mg tablet0.86USD tablet
Naproxen 250 mg tablet0.79USD tablet
Apo-Napro-Na Ds 550 mg Tablet0.7USD tablet
Novo-Naprox Sodium Ds 550 mg Tablet0.7USD tablet
Anaprox 275 mg Tablet0.69USD tablet
Apo-Naproxen Ec 500 mg Enteric-Coated Tablet0.61USD tablet
Mylan-Naproxen Ec 500 mg Enteric-Coated Tablet0.61USD tablet
Novo-Naprox Ec 500 mg Enteric-Coated Tablet0.61USD tablet
Pms-Naproxen Ec 500 mg Enteric-Coated Tablet0.61USD tablet
Naprosyn E 375 mg Enteric-Coated Tablet0.6USD tablet
Naprosyn E 250 mg Enteric-Coated Tablet0.46USD tablet
Apo-Napro-Na 275 mg Tablet0.36USD tablet
Novo-Naprox Sodium 275 mg Tablet0.36USD tablet
Apo-Naproxen Ec 375 mg Enteric-Coated Tablet0.34USD tablet
Mylan-Naproxen Ec 375 mg Enteric-Coated Tablet0.34USD tablet
Novo-Naprox Ec 375 mg Enteric-Coated Tablet0.34USD tablet
Pms-Naproxen Ec 375 mg Enteric-Coated Tablet0.34USD tablet
Apo-Naproxen Ec 250 mg Enteric-Coated Tablet0.26USD tablet
Novo-Naprox Ec 250 mg Enteric-Coated Tablet0.26USD tablet
Apo-Naproxen 500 mg Tablet0.22USD tablet
Novo-Naprox 500 mg Tablet0.22USD tablet
Nu-Naprox 500 mg Tablet0.22USD tablet
Aleve 220 mg gelcap0.19USD capsule
Naprosyn 125 mg/5ml Suspension0.18USD ml
Mediproxen tablet0.17USD tablet
Apo-Naproxen 375 mg Tablet0.15USD tablet
Naproxen sodium 220 mg tablet0.15USD tablet
Novo-Naprox 375 mg Tablet0.15USD tablet
Nu-Naprox 375 mg Tablet0.15USD tablet
CVS Pharmacy all day pain rlf 220 mg tb0.12USD tablet
Wal-proxen 220 mg tablet0.12USD tablet
Apo-Naproxen 250 mg Tablet0.11USD tablet
Novo-Naprox 250 mg Tablet0.11USD tablet
Nu-Naprox 250 mg Tablet0.11USD tablet
All day pain rlf 220 mg caplet0.1USD caplet
Aleve 220 mg caplet0.09USD caplet
Aleve 220 mg tablet0.09USD tablet
Wal-proxen 220 mg caplet0.09USD tablet
Apo-Naproxen 125 mg Tablet0.08USD tablet
All day pain relief 220 mg tablet0.07USD tablet
Naprosyn 25 mg/ml Suspension0.07USD ml
Naproxen sodium 220 mg caplet0.06USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5637320No1994-06-102014-06-10Us
CA2034096No2002-03-262011-01-14Canada
US6060499Yes1998-02-142018-02-14Us
US7332183Yes2006-04-022026-04-02Us
US6586458Yes1998-02-142018-02-14Us
US5872145Yes1998-02-142018-02-14Us
US8022095Yes1998-02-142018-02-14Us
US5900424Yes1996-11-042016-11-04Us
US6369085Yes1998-11-252018-11-25Us
US7411070Yes1998-11-252018-11-25Us
US8852636No2002-05-312022-05-31Us
US8858996No2002-05-312022-05-31Us
US6926907No2003-02-282023-02-28Us
US7745466No1998-10-132018-10-13Us
US9161920No2002-05-312022-05-31Us
US9198888No2002-05-312022-05-31Us
US8945621No2011-10-172031-10-17Us
US8557285No2002-05-312022-05-31Us
US9220698No2011-03-102031-03-10Us
US5714504Yes1995-08-032015-08-03Us
US9345695No2002-05-312022-05-31Us
US9393208No2009-09-032029-09-03Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)153 °CPhysProp
water solubility15.9 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.18HANSCH,C ET AL. (1995)
logS-4.16ADME Research, USCD
Caco2 permeability-4.83ADME Research, USCD
pKa4.15SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0511 mg/mLALOGPS
logP3.29ALOGPS
logP2.99ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)4.19ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity64.85 m3·mol-1ChemAxon
Polarizability24.81 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9948
Blood Brain Barrier+0.6881
Caco-2 permeable+0.9091
P-glycoprotein substrateNon-substrate0.586
P-glycoprotein inhibitor INon-inhibitor0.8747
P-glycoprotein inhibitor IINon-inhibitor0.8396
Renal organic cation transporterNon-inhibitor0.8615
CYP450 2C9 substrateNon-substrate0.7548
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5715
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9521
CYP450 2C19 inhibitorNon-inhibitor0.9447
CYP450 3A4 inhibitorNon-inhibitor0.8905
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8598
Ames testAMES toxic0.5184
CarcinogenicityNon-carcinogens0.8685
BiodegradationNot ready biodegradable0.7809
Rat acute toxicity2.4579 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9588
hERG inhibition (predictor II)Non-inhibitor0.9144
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.95 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-001i-0190000000-64cc22cce1238357760e
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-0f79-0900000000-17f4e93fda31d93027a1
MS/MS Spectrum - Quattro_QQQ 40V, N/ALC-MS/MSsplash10-0fr6-0900000000-4dd08568cff27d62d867
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-000i-0910000000-149b16cac2d80de64d8a
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-00di-0900000000-e7dfead967f29853140d
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-01b9-0900000000-f5f45cee188a08ef62b1
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-014i-0900000000-6c076658da1c69f1b909
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-014i-0900000000-2e1269f26d5b927bca33
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-000i-0900000000-68cd0c5a3fcc15470c14
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-00di-0900000000-64e5ecb5632e32f89b2d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-0910000000-149b16cac2d80de64d8a
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00di-0900000000-e7dfead967f29853140d
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-01b9-0900000000-f5f45cee188a08ef62b1
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-0900000000-6c076658da1c69f1b909
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-0900000000-2e1269f26d5b927bca33
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-000i-0900000000-b913db958cba90673250
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Anisoles / Alkyl aryl ethers / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Naphthalene / Anisole / Alkyl aryl ether / Monocarboxylic acid or derivatives / Ether / Carboxylic acid / Carboxylic acid derivative / Organic oxygen compound / Organic oxide / Hydrocarbon derivative
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
monocarboxylic acid, methoxynaphthalene (CHEBI:7476)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. James MJ, Cook-Johnson RJ, Cleland LG: Selective COX-2 inhibitors, eicosanoid synthesis and clinical outcomes: a case study of system failure. Lipids. 2007 Sep;42(9):779-85. Epub 2007 Jun 2. [PubMed:17541796]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Albertini R, Aimbire F, Villaverde AB, Silva JA Jr, Costa MS: COX-2 mRNA expression decreases in the subplantar muscle of rat paw subjected to carrageenan-induced inflammation after low level laser therapy. Inflamm Res. 2007 Jun;56(6):228-9. [PubMed:17607546]
  2. Dhir A, Naidu PS, Kulkarni SK: Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure. 2007 Dec;16(8):691-7. Epub 2007 Jul 2. [PubMed:17604186]
  3. Kumar P, Padi SS, Naidu PS, Kumar A: Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fundam Clin Pharmacol. 2007 Jun;21(3):297-306. [PubMed:17521299]
  4. White WB: Cardiovascular effects of the selective cyclooxygenase-2 inhibitors. Subcell Biochem. 2007;42:145-58. [PubMed:17612049]
  5. Hassan-Alin M, Naesdal J, Nilsson-Pieschl C, Langstrom G, Andersson T: Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects. Clin Drug Investig. 2005;25(11):731-40. [PubMed:17532719]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Peptostreptococcus magnus
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Binds serum albumin.
Gene Name
pab
Uniprot ID
Q51911
Uniprot Name
Peptostreptococcal albumin-binding protein
Molecular Weight
43057.45 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Banerjee T, Singh SK, Kishore N: Binding of naproxen and amitriptyline to bovine serum albumin: biophysical aspects. J Phys Chem B. 2006 Nov 30;110(47):24147-56. [PubMed:17125386]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954]
  2. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 09:34